A critical appraisal of an article on therapy: Safety and efficacy of oral fusidic acid as a steroid-sparing agent in the treatment of lepra reactions: an assessor-blinded, randomized controlled clinical trial

Authors: Ma. Vinna N. Crisostomo, MD, Mary Jo Kristine S. Bunagan, MD, FPDS

Abstract

A 23-year-old male diagnosed with Hansen’s disease, BBBL, was started on multi-drug therapy (MDT). On his 6th month of therapy, he was started on prednisone 40mg/day for management of type 2 lepra reaction. The dose
of prednisone was decreased by 5 mg every two weeks. On the 12th month of therapy, the dose of prednisone was decreased to 10 mg/day. However, the presence of new generalized papules associated with fever and arthralgia was noted. As an attending physician, one would want to add a steroid-sparing
agent together with prednisone that would help control the lepra reaction of this patient to prevent the consequences of long-term steroid therapy

 

Citation

Crisostomo MV, Bunagan MJ. A critical appraisal of an article on therapy: Safety and efficacy of oral fusidic acid as a steroid-sparing agent in the treatment of lepra reactions: an assessor-blinded, randomized controlled clinical trial. J Phil dermatol Soc. 2018; 27(1): 87-9.

 

Keywords

Hanses, Disease, BBBL, Fusidic Acid

1. Panghi D and Chhabra N. New insights in the pathogenesis of type 1 and type 2 lepra reaction. Indian J Dermatol Venereol and Leprol 2013;79(6)736-749.
2. Kahawita IP, Walker SL, Lockwood DNJ. Leprosy type 1 reactions and erythema nodosum leprosum. Anais Brasileiros de Dermatologia 2008; 83(1):75-82.
3. World Health Organization. WHO expert committee on leprosy: eighth report. Geneva.2010.
4. Franzblau SG, Chan GP, Garcia-Ignacio et al. Clinical trial of fusidic acid for lepromatous leprosy. Antimicrob Agents Chemother 1994; 38(7):1651-4.
5. Gabriel MT, Hipolito RH, Chan GP, Salvador LR et al. Safety and efficacy of oral fusidic acid as a steroid-sparing agent in the treatment of lepra reactions:

More Articles

 

/* ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Conditionally display Abstract button ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ */ /* ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Conditionally display References button ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ */